about
sameAs
Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infectionAn expanded evaluation of protein function prediction methods shows an improvement in accuracyVirtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infectionAIDS vaccine: state of the art at the beginning of the third millennium.AIDS vaccine: efficacy, safety and ethics.In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A VirusesEvolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic.Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China.Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission.Simple criterion for selection of flavonoid compounds with anti-HIV activity.Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control.Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor.A simple method for calculation of basic molecular properties of nutrients and their use as a criterion for a healthy diet.Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.Simple and general criterion for "in silico" screening of candidate HIV drugs.New in silico and conventional in vitro approaches to advance HIV drug discovery and design.In silico analysis suggests interaction between Ebola virus and the extracellular matrixImproving attrition rates in Ebola virus drug discovery.In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.Molecular makeup of HIV-1 envelope protein.HIV-1 gp120 and immune network.Recombination property of the HIV-1 gp120 gene.Safety and ethical consideration of AIDS vaccine.Discovery of new therapeutic targets by the informational spectrum method.The role of long-range intermolecular interactions in discovery of new drugs.Preclinical discovery and development of maraviroc for the treatment of HIV.EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism.AIDSVAX results: an important open question.Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies.Zika virus infection elicits auto-antibodies to C1q.Using electronic biology based platform to predict flu vaccine efficacy for 2018/2019.Prediction of influenza vaccine effectiveness for the influenza season 2017/18 in the US.Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the informational spectrum method.Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target
P50
Q24261190-E96A452D-DDC3-4D7F-86C8-E33C5F36844EQ28596092-6F5E31AE-C9BE-4135-A198-BD5910B019F1Q28649882-785E1262-394E-4C8A-B166-43E49A188263Q30342918-64C14408-B467-4D27-8A4B-2FC4A7FD925BQ30366863-67F38E29-554B-4031-AD9C-E2D2B470B479Q30375878-AE687848-0E70-4732-8C58-DE257ADF4693Q30383187-C108E504-E945-47B1-A228-E354E2E76BDBQ30395076-3841B774-0A59-44CC-8462-73D314BE9AFCQ30430279-0E098C82-2C96-4408-B2F1-B650CF0B2D58Q33267641-CE6A1BC3-4CF1-4F32-9DEB-909BF4393B45Q33427655-54C90C2B-D893-4C11-8565-FC4CAAA45072Q33507177-19B245FB-2C69-4035-BFEE-6DA96FC3D577Q33672130-386B2D5F-E821-4E86-BEFE-D59105E602D3Q34091473-1D9EA9B8-5577-451B-A62C-4F1B5F5D07CEQ34201426-FEFF099E-E62F-4340-9B43-F966FE98714EQ34483539-1C326218-D45F-4486-A152-1E6FB38C0602Q35099536-1479F0B7-0D34-42B1-902E-B2D98A579E5AQ35678774-2820D58E-8CBF-4D83-BCE5-44FF38ECD38BQ35689217-BF6DF77C-6576-4CBA-8484-B53660FA56E4Q35888723-8EB054CD-796F-4BB0-8D88-C3C3352144D3Q35888727-94C1E661-937F-4886-850F-F64F96B6BEE6Q35888737-EBB0A4E1-5B6E-4398-BBFD-05665BD527E4Q35888745-0FBBC44D-D15E-490B-8AEA-81DAF3A2B544Q37294351-2EE9F324-FF25-4589-8E49-4D7FA09D74EDQ38014574-B5E15894-2D77-4C94-8EB6-ADDC86A6C698Q39556338-C5F40ADB-2345-4830-BDC3-D797864B766FQ40055230-EF714E8C-9A5F-4314-8941-E70946C527F1Q42204827-D71E3CBF-F48E-40FA-8D90-340F186F93A6Q42606192-89BB2A90-2993-4D68-9172-7CEFEB0A4415Q43047642-E25810B2-F622-4CAC-B1D2-E1D9175FD6AAQ45218534-E4CC4383-B9A2-4F8B-8158-BC2E6A41109FQ47547783-40653214-9412-43BA-B1D7-63C65C46CC3CQ52595089-17D26F8A-725B-4C58-95B4-F5A29F2339CEQ52657064-04D7CA7D-525B-4DAC-884F-D1E44ECD1514Q54647155-90966192-68AA-4FC6-9826-A12C1E364568Q57015026-00DB504F-9EA9-4E11-8B10-745D46B05043Q94960143-CE0BD3DE-1528-4C5B-832A-10184FD9D6B2
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1980-0927
@en
name
Veljko Veljkovic
@ast
Veljko Veljkovic
@en
Veljko Veljkovic
@es
Veljko Veljkovic
@nl
Veljko Veljkovic
@sl
type
label
Veljko Veljkovic
@ast
Veljko Veljkovic
@en
Veljko Veljkovic
@es
Veljko Veljkovic
@nl
Veljko Veljkovic
@sl
prefLabel
Veljko Veljkovic
@ast
Veljko Veljkovic
@en
Veljko Veljkovic
@es
Veljko Veljkovic
@nl
Veljko Veljkovic
@sl
P106
P21
P31
P496
0000-0002-1980-0927
P569
2000-01-01T00:00:00Z